-
Posted by
Two Blokes May 12 -
Filed in
Stock
-
7 views
For investors seeking differentiated exposure to innovation in the drug development sector, Cavendish believes hVIVO PLC (AIM:HVO) offers a 'compelling' route in. The company runs human challenge trials, a niche but increasingly strategic part of vaccine development that helps accelerate timelines and reduce costs for drugmakers.
